Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

415 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate.
Wood J, Bagi CM, Akuche C, Bacchiocchi A, Baryza J, Blue ML, Brennan C, Campbell AM, Choi S, Cook JH, Conrad P, Dixon BR, Ehrlich PP, Gane T, Gunn D, Joe T, Johnson JS, Jordan J, Kramss R, Liu P, Levy J, Lowe DB, McAlexander I, Natero R, Redman AM, Scott WJ, Town C, Wang M, Wang Y, Zhang Z. Wood J, et al. Among authors: campbell am. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4965-8. doi: 10.1016/j.bmcl.2006.06.041. Epub 2006 Jun 27. Bioorg Med Chem Lett. 2006. PMID: 16806919
In vitro SAR of (5-(2H)-isoxazolonyl) ureas, potent inhibitors of hormone-sensitive lipase.
Lowe DB, Magnuson S, Qi N, Campbell AM, Cook J, Hong Z, Wang M, Rodriguez M, Achebe F, Kluender H, Wong WC, Bullock WH, Salhanick AI, Witman-Jones T, Bowling ME, Keiper C, Clairmont KB. Lowe DB, et al. Among authors: campbell am. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3155-9. doi: 10.1016/j.bmcl.2004.04.015. Bioorg Med Chem Lett. 2004. PMID: 15149665
4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 2. SAR.
Gunn D, Akuche C, Baryza J, Blue ML, Brennan C, Campbell AM, Choi S, Cook J, Conrad P, Dixon B, Dumas J, Ehrlich P, Gane T, Joe T, Johnson J, Jordan J, Kramss R, Liu P, Levy J, Lowe D, McAlexander I, Natero R, Redman AM, Scott W, Seng T, Sibley R, Wang M, Wang Y, Wood J, Zhang Z. Gunn D, et al. Among authors: campbell am. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3053-7. doi: 10.1016/j.bmcl.2005.04.025. Bioorg Med Chem Lett. 2005. PMID: 15890515
Discovery of novel biaryl sulfonamide based Mcl-1 inhibitors.
Follows B, Fessler S, Baumeister T, Campbell AM, Zablocki MM, Li H, Gotur D, Wang Z, Zheng X, Molz L, Nguyen C, Herbertz T, Wang L, Bair K. Follows B, et al. Among authors: campbell am. Bioorg Med Chem Lett. 2019 Aug 15;29(16):2375-2382. doi: 10.1016/j.bmcl.2019.06.008. Epub 2019 Jun 11. Bioorg Med Chem Lett. 2019. PMID: 31235261
Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor.
Caravella JA, Lin J, Diebold RB, Campbell AM, Ericsson A, Gustafson G, Wang Z, Castro J, Clarke A, Gotur D, Josephine HR, Katz M, Kershaw M, Yao L, Toms AV, Barr KJ, Dinsmore CJ, Walker D, Ashwell S, Lu W. Caravella JA, et al. Among authors: campbell am. J Med Chem. 2020 Feb 27;63(4):1612-1623. doi: 10.1021/acs.jmedchem.9b01423. Epub 2020 Feb 12. J Med Chem. 2020. PMID: 31971798
Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.
Lin J, Lu W, Caravella JA, Campbell AM, Diebold RB, Ericsson A, Fritzen E, Gustafson GR, Lancia DR Jr, Shelekhin T, Wang Z, Castro J, Clarke A, Gotur D, Josephine HR, Katz M, Diep H, Kershaw M, Yao L, Kauffman G, Hubbs SE, Luke GP, Toms AV, Wang L, Bair KW, Barr KJ, Dinsmore C, Walker D, Ashwell S. Lin J, et al. Among authors: campbell am. J Med Chem. 2019 Jul 25;62(14):6575-6596. doi: 10.1021/acs.jmedchem.9b00362. Epub 2019 Jul 8. J Med Chem. 2019. PMID: 31199148
The Power of International Cooperation.
Bizzini M, Campbell AM, Hoogenboom B, Voight M. Bizzini M, et al. Among authors: campbell am. Int J Sports Phys Ther. 2024 Nov 2;19(11):1289. doi: 10.26603/001c.125160. eCollection 2024. Int J Sports Phys Ther. 2024. PMID: 39502552 Free PMC article. No abstract available.
Unrecognised actionability for breast cancer risk variants identified in a national-level review of Australian familial cancer centres.
Fortuno C, Cops EJ, Davidson AL, Hadler J, Innella G, McKenzie ME, Parsons M, Campbell AM, Dubowsky A, Fargas V, Field MJ, Mar Fan HG, Nichols CB, Poplawski NK, Warwick L, Williams R, Beshay V, Edwards C, Johns A, McPhillips M, Kumar VS, Scott R, Williams M, Scott H, James PA, Spurdle AB. Fortuno C, et al. Among authors: campbell am. Eur J Hum Genet. 2024 Oct 14. doi: 10.1038/s41431-024-01705-9. Online ahead of print. Eur J Hum Genet. 2024. PMID: 39402389
415 results